Indivior Pharmaceuticals — Business Overview

What does Indivior do?

Indivior is a specialty pharmaceutical company focused exclusively on treating opioid use disorder (OUD). It develops and sells prescription medications that help patients manage OUD — a chronic, relapsing brain disease characterized by compulsive opioid use. The company describes itself as the market leader in long-acting injectable medications for this condition and has been involved in buprenorphine-based treatment for over 25 years.

Indivior sells two core products, with a clear shift toward its injectable product as the growth driver:

SUBLOCADE is the company's primary commercial focus. It became the largest product by revenue in 2022 and now accounts for the majority of sales. SUBOXONE Film, once the flagship product, has faced heavy generic competition in the U.S. and is no longer actively promoted there by the sales force.

How does Indivior make money?

Indivior earns revenue by selling prescription branded pharmaceuticals through specialty pharmacies, distributors, and directly to organized health systems. Because SUBLOCADE must be administered by a healthcare provider (it cannot be dispensed directly to patients), it flows through specialty pharmacies and distributors rather than traditional retail pharmacies. SUBOXONE Film, in contrast, can be dispensed at a pharmacy and reaches patients through major wholesale pharmaceutical companies. Indivior's three largest wholesale customers accounted for 51% of global net revenues in 2025.

Reimbursement from government and commercial insurance is central to the revenue model. A large share of OUD patients are covered by Medicaid (the U.S. government insurance program for lower-income individuals), since many people with OUD are unemployed or lack employer-sponsored coverage. Indivior maintains coverage with approximately 90% of U.S. payors. Over 95% of SUBLOCADE patients enrolled in its co-pay program pay $0 out of pocket, meaning the real payers are insurers and government programs. This makes the company highly sensitive to Medicaid and government healthcare policy.

What market does Indivior operate in?

Indivior operates in the medication for opioid use disorder (MOUD) market, which addresses a large and underserved patient population. In the U.S. alone, approximately 4.8 million people had OUD in 2024, yet only 17% (around 818,000 people) received any medication-based treatment. Globally, the UN estimates 64 million people live with a substance use disorder, with opioids responsible for roughly two-thirds of drug-related deaths. This treatment gap represents a significant unmet need and potential market opportunity.

Secular trends are broadly supportive of the MOUD category. Fentanyl — a synthetic opioid 30 to 50 times more potent than heroin — now drives approximately 96% of opioid overdose deaths in the U.S. This has intensified urgency around treatment access and may increase demand for effective medications like SUBLOCADE, which clinical data suggests may help block fentanyl's effects at higher doses. Policy-level tailwinds include inclusion of OUD treatment in U.S. Sustainable Development Goals and bipartisan support for expanding access. Headwinds include stigma around addiction treatment, regulatory complexity around controlled substances, and reliance on government reimbursement programs that face periodic policy uncertainty.

Who are Indivior's main competitors?

SUBLOCADE faces a single branded competitor in the injectable buprenorphine space, while SUBOXONE Film faces four generic competitors. In the U.S., Camurus (partnered with Braeburn) markets BRIXADI, another long-acting injectable buprenorphine product. Outside the U.S., the same product is sold as BUVIDAL and has first-mover advantage in most international markets, including a well-established position in Australia. For SUBOXONE Film, generic versions have eroded Indivior's U.S. market share to an average of 14.2% category share in 2025. In France and Germany, generics have competed with SUBUTEX and SUBOXONE tablets since 2010 and 2018, respectively.

Indivior's primary competitive advantages are its patent protection on SUBLOCADE and its clinical differentiation. SUBLOCADE is protected by multiple U.S. patents extending as far as 2044. It is the only monthly injectable buprenorphine that can be initiated on day one without requiring a prior period of oral medication — a label change approved by the FDA in February 2025. The company also points to SUBLOCADE's closed distribution system (patients never handle the drug directly) as reducing diversion and misuse risk compared to oral alternatives, which may appeal to institutional buyers like prisons and health systems. The industry for branded MOUD injectables is essentially a two-player market in the U.S., while oral buprenorphine is highly genericized and fragmented.

Where does Indivior operate?

The United States is overwhelmingly the most important market, generating 85% of net revenues in both 2024 and 2025. Indivior sells only SUBLOCADE and SUBOXONE Film in the U.S. and deploys its full commercial infrastructure there — a field sales force of Clinical Specialists, managed care teams, criminal justice access directors, and medical affairs personnel. The U.S. is described as generating an even larger share of profitability than its 85% revenue contribution suggests.

Outside the U.S., Indivior operates in Canada, Australia, France, and Germany — and is actively pulling back from other markets. In October 2025, the company announced it would cease operations in the U.K., Ireland, Sweden, Israel, Finland, and Italy. It retains a sales force in Canada and Australia, maintains a presence in France, and sells in Germany without local operations. Indivior manufactures its buprenorphine active pharmaceutical ingredient (the raw chemical used in its drugs) at a plant in Hull, U.K., which it is keeping even as it exits the surrounding market. It is also building out a manufacturing facility in Raleigh, North Carolina, to reduce reliance on its third-party contract manufacturer (Curia) for SUBLOCADE production. As of December 31, 2025, 593 of its 838 employees were based in the U.S., with 245 outside it.